India, Sept. 24 -- Vitruvias Therapeutics Inc. announced on 21 August a nationwide consumer-level recall of Lot 504950 of Thyroid Tablets, USP 30 mg, after laboratory testing confirmed the tablets contained more active medication than the manufacturer specified. The Auburn-based pharmaceutical firm discovered during routine quality-control procedures that the affected lot possessed potential for superpotency-a critical finding for a medication where even modest dosage variations can produce serious clinical consequences.

The company voluntarily initiated the recall at the consumer level, the most expansive recall classification indicating the medication has already reached patients rather than remaining in warehouse inventory. This eleva...